The humoral immune response can be an important component of protective immunity against infectious agents, and one strategy for immunoprophylaxis against AIDS may be the administration of an immunogen designed to elicit virusneutralizing antibodies. Although many laboratories have demonstrated that all or parts of the human immunodeficiency virus (HIV) envelope glycoproteins induce neutralizing antibodies when administered in Freund's adjuvant (9, 18, 22, 33, 34, 36) , very few studies have been done using clinically approved adjuvants. Aluminum hydroxide has generally only been used in studies involving primates, and in most cases in which neutralization has been observed, the titers have been low (3, 4, 6, 33) . However, significant progress toward the development of an HIV vaccine has been made recently with the demonstration that recombinant gp120 formulated in aluminum hydroxide can elicit protective immunity in chimpanzees against a homologous strain of HIV type 1 (HIV-1) (5). The protection was correlated with the induction of high-titer neutralizing antibodies and also with the presence of antibodies targeted against the principal neutralizing determinant of HIV (19) contained within the disulfide-cross-linked third variable domain (V3 loop) of gp120. Although no adverse side effects were observed in the immunized chimpanzees, the immunosuppressive effects that may result from gp120 binding to CD4 and inhibiting T-cell function in humans should still be taken into consideration (10, 13, 24, 31) . The use of immunogens containing neutralization determinants but deficient in CD4 binding may therefore be advantageous. Surprisingly, despite consider-* Corresponding author. able interest in the ability of V3 loop peptides to elicit neutralizing antibodies (19, 34, 35, 38) (1, 30) . The Ty particle itself can tolerate a wide range of additional protein sequence without disruption, allowing small peptide-sized fragments, protein domains, and full-length proteins to be accommodated (1, 15, 30) . In addition, any hybrid Ty viruslike particle (Ty-VLP) can be purified by using a generic protocol based on the physical properties of the particle. To produce hybrid HIV V3-Ty-VLPs containing a V3 loop, synthetic oligomers encoding gpl20 amino acids 295 to 333 from isolate HXB2 (14) were inserted into the BamHI site of plasmid pMA5620 (1) (Fig. la) . The resulting plasmid (pOGS514) therefore contained a Ty-HIV fusion gene under the control of the efficient yeast phosphoglycerate kinase promoter (Fig. la) . After transformation of plasmid pOGS514 into yeast cells, the fusion protein was expressed at high levels and assembled into 50-nm particles (Fig. lb) . These hybrid HIV V3-Ty-VLPs were purified by a standard procedure that has been described previously (15) , and the presence of the V3 sequence was confirmed by Western immunoblotting (data not shown). The location of the HIV component was analyzed by immunogold electron microscopy with a V3 loopspecific monoclonal antibody (MAb) (Fig. lc) To evaluate the immunogenicity of the HIV V3-Ty-VLPs in a formulation that has been previously approved for use in humans, we administered the particles to rabbits as an aluminum hydroxide precipitate (Table 1 , bottom). Surprisingly, both the anti-gpl2O serum antibody titers and virusneutralizing titers obtained against HIV isolate IIIB were at least equivalent to, and in some cases higher than, the responses obtained with Freund's adjuvant. The specificity of the neutralization response was assessed with the divergent HIV isolates RF (40) and MN (17) . Sera taken from animals Al, A2, and A3 after the fifth booster immunization showed no significant neutralization of either of these isolates. The longevity of the anti-IIIB response was evaluated by analyzing sera taken from two of the immunized animals every 2 weeks after the final boost for a period of 10 weeks ( Table 2 ). The neutralizing antibody titers of animal Al remained constant at 1/512 for 8 weeks after the final boost and then dropped to 1/64, whereas the ability of sera from animal A3 to neutralize HIV isolate IIIB declined gradually throughout the 10-week period, with a half-life of 20 to 30 days. However, in both animals, significant levels of serum and neutralizing antibodies were still present 10 weeks after the last immunization.
Javaherian et al. (19) and Meloen et al. (29) have recently demonstrated that the major neutralizing epitope of HIV-1 isolate IIIB is defined by eight amino acids (QRGPGRAF) at the tip of the V3 loop ( Fig. 2A) . We therefore investigated whether the antibodies raised against the HIV V3-Ty-VLPs JLg/mI gpl2O ILg/ml gp120 contained a significant number of molecules that bound to this region. The ability of serum from animal Al to bind intact recombinant gpl2O and gpl2O that had been proteolytically cleaved at a single site within the V3 loop (41) (Fig. 2A) was compared with the binding of three characterized gpl2O-specific MAbs. The binding profiles of the rabbit Al serum, MAb 110.5 (23) , and MAb 0.5,3 (25) were comparable, and binding was reduced when the epitope at the tip of the loop was destroyed by cleavage (Fig. 2B) . In contrast, the binding of MAb 9284 (39) was unaffected by cleavage of gpl2O. It has been shown previously that MAbs 110.5 and 0.5, bind to sequences that include the tip of the loop (26, 39) , whereas MAb 9284 binds an amino acid sequence on the left-hand side that does not overlap the Arg-Ala cleavage site (39) (Fig.  2A) . The binding profile of the anti-HIV V3-Ty-VLP serum is therefore consistent with a significant proportion of the antibodies being targeted to the major neutralizing epitope as delineated by Javaherian et al. (19) (Fig. 3) (2-4, 6, 33) . Although it is difficult to make comparisons between species, significant neutralizing antibodies were still present in rabbits immunized with hybrid HIV V3-Ty-VLPs 10 weeks after the final boost. However, for an HIV vaccine to be efficacious in humans, it may be necessary to maintain high levels of antibodies for several months. Second, if the levels of neutralizing antibodies gradually decline, a rapid recall of the response must be demonstrated after exposure to the virus. Although boosting with V3-Ty-VLPs resulted in recall of the antibody response to the V3 loop, it is possible that both Ty-specific and V3-specific T-helper cells were involved. In a natural infection, only HIV-specific responses will be of relevance, and it may therefore be necessary to increase the repertoire of HIV-specific T-cell epitopes in the vaccine formulation. Third, any vaccine candidate based on gpl20 must take into account the sequence variability observed between isolates and the type specificity of the antibody response to the V3 loop determinant. One approach to overcome these problems might be to use a mixture of antigens containing V3 loop regions from the most frequently occurring isolates (12) in conjunction with additional T-helper-cell epitopes (7, 8) and specific immune enhancers such as T-or B-cell-stimulating cytokines. 
